

COVERAGE DETERMINATION REQUEST FORM

EOC ID:

Elixir Opioid Review (200 MME)

Phone: 800-361-4542 Fax back to: 866-414-3453

Elixir manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable	r):
*Please note that Elixir will process the request as writt	en, including drug name, with n	o substitution.
	☐ Expedited/Urgent	
Drug Name and Strength:		
Directions / SIG:		
Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.		
Q1. Is this request for initial or continuing therapy?		
☐ Initial therapy	☐ Continuing therapy	
O2 For CONTINUING THEDADY places provide the s	start data (MM/VV):	
Q2. For CONTINUING THERAPY, please provide the s	start date (IVIIVI/ 1 1).	
Q3. Please indicate the patient's diagnosis for the request	ed medication:	
☐ Pain secondary to a diagnosis of active cancer		
☐ Pain secondary to a terminal illness		
☐ Sickle-cell disease		
☐ Acute pain: post-surgical pain		
☐ Moderate-to-severe chronic pain		
☐ Other		
Q4. If the patient's diagnosis is OTHER, please specify	below:	
Q5. Does the prescriber attest to utilizing the safety meas Prevention (CDC) Guideline for Prescribing Opioids for Ch		sease Control and
☐ Yes	□ No	
Q6. Has the prescriber reviewed the appropriate state pre	scription drug monitoring program	?



COVERAGE DETERMINATION REQUEST FORM

EOC ID:

Elixir Opioid Review (200 MME)

Phone: 800-361-4542 Fax back to: 866-414-3453

Elixir manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	Prescriber Name:		
☐ No ☐ Missouri/Guam only: No, my state does not have an	available prescription drug monitoring program		
Q7. Has the patient been assessed for contraindications to known/suspected paralytic ileus, etc.)?	o opioid therapy (e.g. significant respiratory depression,		
☐ Yes	□ No		
Q8. If patient is female between 18-45 years old, has the prescriber discussed risk of neonatal abstinence syndrome and provided counseling on contraceptive options?			
☐ Yes ☐ No	☐ Not applicable		
Q9. For post-surgical pain, has the patient been provided instruction on how to integrate their post-operative opioid therapy into their existing medication regimen (including titration of an existing opioid regimen)? Yes No The request is not for post-surgical pain			
Q10. Has the patient been counseled on the risks of an opioid overdose and been provided with an opportunity to obtain a prescription or other access to naloxone in addition to their opioid prescriptions?			
☐ Yes	□ No		
Q11. Does the prescriber attest that a cumulative daily MME (Morphine Milligram Equivalents) of 200 or greater is medically necessary for this patient?			
☐ Yes ☐ No	□ N/A		
Q12. The prescriber may provide any additional rationale in order to justify coverage of the requested medication and quantity.			
Prescriber Signature	Date		



COVERAGE DETERMINATION REQUEST FORM

EOC ID:

Elixir Opioid Review (200 MME)

Phone: 800-361-4542 Fax back to: 866-414-3453

Elixir manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	Prescriber Name:

hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document